Hudson Bay Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,190,416
| Closed | -$47.9M | – | 1362 |
|
|
2026
Q1 | $47.9M | Buy |
1,190,416
+10,588
| +0.9% | +$228K | 0.17% | 107 |
|
|
2025
Q4 | $29.6M | Buy |
1,179,828
+761,328
| +182% | +$17.9M | 0.1% | 180 |
|
|
2025
Q3 | $9.47M | Sell |
418,500
-56,500
| -12% | -$1.32M | 0.03% | 369 |
|
|
2025
Q2 | $8.22M | Buy |
475,000
+164,300
| +53% | +$3.04M | 0.03% | 408 |
|
|
2025
Q1 | $6.8M | Sell |
310,700
-34,300
| -10% | -$948K | 0.02% | 523 |
|
|
2024
Q4 | $11M | Buy |
345,000
+85,000
| +33% | +$2.56M | 0.04% | 346 |
|
|
2024
Q3 | $7.5M | Buy |
260,000
+145,000
| +126% | +$5.37M | 0.03% | 345 |
|
|
2024
Q2 | $4.41M | Buy |
115,000
+80,000
| +229% | +$3.62M | 0.02% | 401 |
|
|
2024
Q1 | $2.06M | Buy |
+35,000
| New | +$2.23M | 0.01% | 450 |
|
|
2023
Q4 | – | Sell |
-12,500
| Closed | -$476K | – | 716 |
|
|
2023
Q3 | $476K | Buy |
+12,500
| New | +$549K | ﹤0.01% | 603 |
|
|
2023
Q2 | – | Sell |
-50,000
| Closed | -$3.3M | – | 851 |
|
|
2023
Q1 | $3.3M | Buy |
+50,000
| New | +$2.89M | 0.03% | 407 |
|
|
2020
Q4 | – | Sell |
-60,000
| Closed | -$1.81M | – | 592 |
|
|
2020
Q3 | $1.81M | Buy |
+60,000
| New | +$1.79M | 0.03% | 373 |
|
Other funds holding APLS
Hudson Bay Capital Management's APLS Position: Q2 2026 in Review
Hudson Bay Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,190,416 shares — an estimated $47.9M sold.
Hudson Bay Capital Management first reported a position in APLS in Q3 2020 and held it in 12 quarters. The position peaked at $47.9M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Hudson Bay Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Hudson Bay Capital Management sold 1,190,416 Apellis Pharmaceuticals shares in Q2 2026, an estimated $47.9M.
- Hudson Bay Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2020 and held it in 12 quarters.
- Hudson Bay Capital Management's Apellis Pharmaceuticals position peaked at $47.9M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.